UCSF

Interoperability Champion Steven Lane, MD, MPH, Joins Health Gorilla as Chief Medical Officer

Retrieved on: 
Tuesday, August 16, 2022 - 4:00pm

Mountain View, California, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Health Gorilla, a leading Health Information Network and interoperability provider, announced today it has appointed Steven Lane, MD, MPH, former Clinical Informatics Director at Sutter Health, as Chief Medical Officer (CMO).

Key Points: 
  • Mountain View, California, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Health Gorilla, a leading Health Information Network and interoperability provider, announced today it has appointed Steven Lane, MD, MPH, former Clinical Informatics Director at Sutter Health, as Chief Medical Officer (CMO).
  • I am very excited to see TEFCA implemented and to join Health Gorilla in their journey to serve as one of the first Qualified Health Information Networks.
  • Steven is one of the nations leading experts on health data interoperability, privacy, and policy, and I am absolutely thrilled to have him join our team, said Steve Yaskin, Chief Executive Officer and co-founder of Health Gorilla.
  • Founded in 2014, Health Gorilla is a National Health Information Network (HIN) and interoperability platform providing permitted access to actionable patient data.

CipherHealth marks stellar momentum, prepares new avenues of growth

Retrieved on: 
Tuesday, August 16, 2022 - 2:00pm

NEW YORK, Aug. 16, 2022 /PRNewswire/ -- CipherHealth, a recognized leader and innovator in patient-centered communications, engagement, and insights for the nation's leading healthcare systems, is hitting the second half of the year on a strong wave of growth and momentum. Having secured a slate of new high-profile customers in 2022, while at the same time rolling out strategic new solutions and solution enhancements, CipherHealth is well-poised to help leading hospitals meet the challenges of an industry characterized by accelerating innovation, transformation, and consolidation.

Key Points: 
  • Several CipherHealth customers have already adopted these new pre-care solution sets.
  • The recognition comes amid organization-wide initiatives to bolster professional development, supercharge career growth, and prioritize diversity, equity, and inclusion.
  • "From every angle, the last several months have been remarkable for our team at CipherHealth," said Summer Brown, Chief Customer Officer.
  • CipherHealth is an award-winning digital patient engagement company committed to enhancing communication and coordination throughout the care continuum.

UNITY Biotechnology to Host Investor Call on 12- and 18-week Data from Phase 2 BEHOLD Study of UBX1325 in Patients with DME

Retrieved on: 
Thursday, August 11, 2022 - 10:45pm

ET, with retinal expert Robert Bhisitkul, M.D., Ph.D., Professor of Ophthalmology, UCSF.

Key Points: 
  • ET, with retinal expert Robert Bhisitkul, M.D., Ph.D., Professor of Ophthalmology, UCSF.
  • The live webcast can be accessed in the Investors and Media section of our website, www.unitybiotechnology.com , under Events & Presentations or by clicking here .
  • UNITY is developing a new class of therapeutics to slow, halt, or reverse diseases of aging.
  • UNITYs current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases.

Collective Health Names Mark Laret to Board of Directors

Retrieved on: 
Tuesday, August 9, 2022 - 2:05pm

Today, Collective Health announced the addition of Mark Laret, a nationally recognized healthcare operator and innovator, to its board of directors.

Key Points: 
  • Today, Collective Health announced the addition of Mark Laret, a nationally recognized healthcare operator and innovator, to its board of directors.
  • Mark retired from his post as UCSF Health President and CEO in December of last year, after 20+ years of service.
  • Collective Health spans all three and I am excited to lend my expertise and experience to helping them navigate this next phase of growth.
  • Mark is intimately familiar with the complexities of our healthcare system, said Ali Diab, CEO and Founder of Collective Health.

Movano Ring Exceeds Accuracy Targets for SpO2 and Heart Rate Monitoring in Initial Hypoxia Study; Company Eyes FDA Submission

Retrieved on: 
Tuesday, August 9, 2022 - 2:00pm

PLEASANTON, Calif., Aug. 9, 2022 /PRNewswire/ -- Movano Inc. (NASDAQ: MOVE), a purpose-driven healthcare solutions company at the intersection of medtech and consumer devices, announces today the successful completion of a study with the University of California San Francisco (UCSF) to assess the accuracy of the Movano Ring's blood oxygen saturation (SpO2) and heart rate data. With results that exceeded the requirements of the industry standard used by FDA for evaluating SpO2 devices, this successful study is a promising step toward the company's goal to provide medically-validated data to consumers and healthcare professionals.

Key Points: 
  • The prototype also measured heart rate during this time and participants' heart rate varied from 60 to 120 beats per minute as they were being deprived of oxygen.
  • In addition, the Ring also estimated heart rate with accuracy commensurate with the FDA's standards.
  • As Movano eyes its first FDA submission, validating the device's ability to measure blood oxygen levels, heart rate and other vitals is a top priority for the company.
  • This hypoxia study is a promising display of the quality metrics our ring can deliver," said John Mastrototaro, CEO of Movano.

MarinHealth Medical Center Launches APeX, UCSF Health’s Version of Epic Electronic Health Record System, to Provide More Coordinated Care

Retrieved on: 
Monday, August 8, 2022 - 5:00pm

MarinHealth today announced the launch of a new electronic health record system called APeX, the UCSF version of EPIC, the largest and most widely used medical record system in the world.

Key Points: 
  • MarinHealth today announced the launch of a new electronic health record system called APeX, the UCSF version of EPIC, the largest and most widely used medical record system in the world.
  • We are committed to providing high-quality care and an exceptional patient experience for our patients and communities, said Karin Shavelson, MD, MarinHealth Medical Centers chief medical officer.
  • MarinHealth and UCSF Healths strategic alliance was formed to further improve the quality of care and patient experience for the communities we jointly serve.
  • The MarinHealth entities ( Medical Center , Foundation , and Medical Network ) work closely to deliver coordinated, patient-centric care to the people of Marin and the greater North Bay.

Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE®, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis

Retrieved on: 
Saturday, August 6, 2022 - 1:50am

MYFEMBREE offers an effective, once-daily treatment option for the management of moderate to severe pain associated with endometriosis, with a treatment duration of up to 24 months.

Key Points: 
  • MYFEMBREE offers an effective, once-daily treatment option for the management of moderate to severe pain associated with endometriosis, with a treatment duration of up to 24 months.
  • MYFEMBREE is available immediately to patients with moderate to severe pain associated with endometriosis with a prescription from their healthcare provider.
  • Myovant and Pfizer also are committed to supporting women in the U.S. who are prescribed MYFEMBREE throughout their treatment journeys.
  • Food and Drug Administration for the management of moderate to severe pain associated with endometriosis, with a treatment duration of up to 24 months.

PNOC FOUNDATION, A LEADING NON-PROFIT TO FURTHER ADVANCEMENTS IN PEDIATRIC BRAIN CANCER, ANNOUNCES THE APPOINTMENT OF DR. SUNG POBLETE, PhD, RN TO ITS BOARD OF DIRECTORS

Retrieved on: 
Tuesday, August 2, 2022 - 2:00pm

SAN RAFAEL, Calif., Aug. 2, 2022 /PRNewswire/ -- The Pacific Pediatric Neuro-Oncology Consortium Foundation (PNOC Foundation), a non-profit dedicated to supporting advancements in childhood brain cancer research and clinical trials, announces the appointment of Dr. Sung Poblete, PhD, RN and CEO of FARE (Food Allergy Research & Education) to its Board of Directors.

Key Points: 
  • Pediatric brain cancer is the leading cause of cancer-related death for children, yet a disproportionately low amount of federal research funding goes to pediatric brain cancer.
  • The PNOC Foundation's vision is to lose no child to brain cancer, and to improve the quality of life for those fighting and surviving pediatric brain cancer.
  • About The Pacific Pediatric Neuro-Oncology Consortium (PNOC) Foundation:
    The Pacific Pediatric Neuro-Oncology Consortium Foundation ( PNOC Foundation ) is a non-profit dedicated to supporting the advancements in childhood brain cancer research.
  • Since its founding, the PNOC Foundation has granted over $$2.67M to support the work of the PNOC Scientific consortium (PNOC).

OptraSCAN® receives CE-IVDR for OS-Ultra™ high-performance Digital Pathology System

Retrieved on: 
Thursday, July 28, 2022 - 2:00pm

The tray and basket system used by OS-Ultrascanners are designed to efficientlytransfer and position slides for scanning and prevent slide handling mistakes.

Key Points: 
  • The tray and basket system used by OS-Ultrascanners are designed to efficientlytransfer and position slides for scanning and prevent slide handling mistakes.
  • OptraSCAN's full digital pathology solutions include scanning devices, image management and viewing software, telepathology software, and image analysis solutions for biomarker and morphometry.
  • Chairman of pathology at Stanford, University of British Columbia, Duke Medical, UCSF, and Yale are advisors and mentors to OptraSCAN teams.
  • OptraSCAN are pioneers in the On-Demand Digital Pathology System, focused on delivering fully integrated, affordable solutions that will maximize your return on investment and improve the performance of your pathology services.

Vicinitas Therapeutics Launches With $65 Million in Series A Financing to Advance Precision Medicines to Stabilize Key Proteins to Treat Disease

Retrieved on: 
Thursday, July 28, 2022 - 12:00pm

Vicinitas Therapeutics, a biotechnology company advancing a proprietary targeted protein stabilization platform to develop novel therapeutics in cancer and genetic disorders, today launched with $65 million in Series A financing.

Key Points: 
  • Vicinitas Therapeutics, a biotechnology company advancing a proprietary targeted protein stabilization platform to develop novel therapeutics in cancer and genetic disorders, today launched with $65 million in Series A financing.
  • Many diseases, including cancer and monogenic diseases, are often caused by specific proteins that are abnormally degraded and lost from the cell.
  • In cancer, protective tumor suppressors are aberrantly destroyed, allowing cancer cells to circumvent cell death, thus promoting unobstructed cell proliferation.
  • Vicinitas Therapeutics is a biotechnology company focused on targeted protein stabilizers known as Deubiquituinase Targeting Chimeras (DUBTACs).